These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 18241816

  • 1. Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary.
    Ødegaard E, Davidson B, Elgaaen BV, Fagerhol MK, Engh V, Onsrud M, Staff AC.
    Am J Obstet Gynecol; 2008 Apr; 198(4):418.e1-7. PubMed ID: 18241816
    [Abstract] [Full Text] [Related]

  • 2. Plasma calprotectin concentrations in women with endometrial carcinoma.
    Ni Bhriain H, Trovik J, Wik E, Stefansson IM, Akslen LA, Salvesen HB, Staff AC.
    Gynecol Oncol; 2009 Sep; 114(3):491-5. PubMed ID: 19577278
    [Abstract] [Full Text] [Related]

  • 3. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
    Dong L, Chang XH, Ye X, Zhu LR, Zhao Y, Tian L, Cheng HY, Li XP, Zhang H, Liao QP, Fu TY, Cheng YX, Cui H.
    Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
    [Abstract] [Full Text] [Related]

  • 4. Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer.
    Jackson D, Craven RA, Hutson RC, Graze I, Lueth P, Tonge RP, Hartley JL, Nickson JA, Rayner SJ, Johnston C, Dieplinger B, Hubalek M, Wilkinson N, Perren TJ, Kehoe S, Hall GD, Daxenbichler G, Dieplinger H, Selby PJ, Banks RE.
    Clin Cancer Res; 2007 Dec 15; 13(24):7370-9. PubMed ID: 18094419
    [Abstract] [Full Text] [Related]

  • 5. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer.
    Dieplinger H, Ankerst DP, Burges A, Lenhard M, Lingenhel A, Fineder L, Buchner H, Stieber P.
    Cancer Epidemiol Biomarkers Prev; 2009 Apr 15; 18(4):1127-33. PubMed ID: 19336561
    [Abstract] [Full Text] [Related]

  • 6. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma.
    Sorak M, Arsenijević S, Lukić G, Arsenijević N, Ristić P, Pavlović S, Popović S, Baskić D.
    J BUON; 2007 Apr 15; 12(1):99-104. PubMed ID: 17436409
    [Abstract] [Full Text] [Related]

  • 7. Elevated serum RANTES levels in patients with ovarian cancer correlate with the extent of the disorder.
    Tsukishiro S, Suzumori N, Nishikawa H, Arakawa A, Suzumori K.
    Gynecol Oncol; 2006 Sep 15; 102(3):542-5. PubMed ID: 16510173
    [Abstract] [Full Text] [Related]

  • 8. Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis.
    Tsukishiro S, Suzumori N, Nishikawa H, Arakawa A, Suzumori K.
    Gynecol Oncol; 2005 Feb 15; 96(2):516-9. PubMed ID: 15661245
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Diagnostic markers for early detection of ovarian cancer.
    Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, Tenthorey J, Leiser A, Flores-Saaib R, Yu H, Azori M, Rutherford T, Schwartz PE, Mor G.
    Clin Cancer Res; 2008 Feb 15; 14(4):1065-72. PubMed ID: 18258665
    [Abstract] [Full Text] [Related]

  • 11. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
    Dong L, Cui H, Li XP, Sun LF, Chang XH, Liang XD, Zhu HL.
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jan 15; 43(1):5-8. PubMed ID: 18366923
    [Abstract] [Full Text] [Related]

  • 12. [The plasma levels and diagnostic utility of granulocyte colony stimulating factor (G-CSF) and macrophage - colony stimulating factor (M-CSF) in ovarian cancer patients].
    ławicki S, Czygier M, Gacuta-Szumarska E, Knapp P, Szmitkowski M.
    Pol Merkur Lekarski; 2006 Nov 15; 21(125):465-8. PubMed ID: 17345841
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Statistical interpretation of CA125 and Bcl-2 in serum of patients with late stage ovarian cancer.
    Camlica H, Duranyildiz D, Tas F, Yasasever V.
    Am J Clin Oncol; 2008 Dec 15; 31(6):585-8. PubMed ID: 19060592
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
    Ayhan A, Guven S, Guven ES, Kucukali T.
    Acta Obstet Gynecol Scand; 2007 Dec 15; 86(4):484-90. PubMed ID: 17486473
    [Abstract] [Full Text] [Related]

  • 17. [Clinical study of autoantibody spectrum against ovarian cancer associated antigens combined with CA(125) in detecting and monitoring ovarian cancer].
    Yang ZJ, Yang G, Jiang YM, Ran YL, Yang ZH, Zhang W, Zhang JQ, Pan ZM, Li L.
    Zhonghua Fu Chan Ke Za Zhi; 2011 Feb 15; 46(2):113-8. PubMed ID: 21426769
    [Abstract] [Full Text] [Related]

  • 18. Calprotectin plasma level is elevated in preeclampsia.
    Holthe MR, Staff AC, Berge LN, Fagerhol MK, Lyberg T.
    Acta Obstet Gynecol Scand; 2005 Feb 15; 84(2):151-4. PubMed ID: 15683375
    [Abstract] [Full Text] [Related]

  • 19. Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer.
    Staff AC, Bock AJ, Becker C, Kempf T, Wollert KC, Davidson B.
    Gynecol Oncol; 2010 Sep 15; 118(3):237-43. PubMed ID: 20576287
    [Abstract] [Full Text] [Related]

  • 20. Serum insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-3, leptin concentrations and insulin resistance in benign and malignant epithelial ovarian tumors in postmenopausal women.
    Serin IS, Tanriverdi F, Yilmaz MO, Ozcelik B, Unluhizarci K.
    Gynecol Endocrinol; 2008 Mar 15; 24(3):117-21. PubMed ID: 18335323
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.